Aquestive Therapeutics, Inc. revised earnings guidance for the full year 2023. For the period, the company expected total revenue to be in the range of $47 million to $50 million compared to previous guidance of $44 million to $48 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.215 USD | +0.47% | +4.21% | +59.16% |
05-10 | Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target | MT |
05-08 | Transcript : Aquestive Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+59.16% | 291M | |
+31.37% | 588B | |
-2.63% | 364B | |
+20.67% | 326B | |
+5.83% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+11.19% | 167B | |
+0.05% | 161B |
- Stock Market
- Equities
- AQST Stock
- News Aquestive Therapeutics, Inc.
- Aquestive Therapeutics, Inc. Revises Earnings Guidance for the Full Year 2023